Patent application number | Description | Published |
20080221281 | CONTINUOUS PROCESS AND SYSTEM OF PRODUCING POLYETHER POLYOLS - A continuous process and system for producing polyether polyols that allows for continuously adding an unreacted oxide to a loop reactor while adding at least one thermally deactivating catalyst capable of thermally deactivating prior to decomposition of polyether polyol which can allow for greater concentrations of unreacted oxides and/or a rate of reaction in the loop reactor is at a rate at least two times faster than a rate of reaction in a loop reactor containing less than 14 weight percent unreacted oxide. In a preferred embodiment, the catalyst is a double metal cyanide catalyst and a plug flow reactor is formed in series with the loop reactor wherein neither reactor contains a vapor space. | 09-11-2008 |
20100069515 | MIXED ALCOHOL SYNTHESIS WITH ENHANCED CARBON VALUE USE - The present invention provides a method for simplifying manufacture of a mixed alcohol or mixed oxygenate product from synthesis gas. The mixed alcohol or mixed oxygenate product contains ethanol and other oxygenates with two or more carbon atoms per molecule. The method includes stripping a portion of carbon dioxide and inert gases contained in a mixed alcohol synthesis reaction product using a methanol-containing stream, such as one produced as part of the method, as a medium to absorb said carbon dioxide and inert gases and recycling light products and heavy products to one or more of synthesis gas generation, mixed alcohol synthesis and separation of desired mixed alcohol or mixed oxygenate products from other components of a mixed alcohol synthesis stream. The present invention also provides downstream processing of the mixed alcohol or mixed oxygenate product by subjecting the product to a dehydration step in order to convert at least ethanol, preferably at least ethanol and propanol, to their corresponding olefins (e.g. ethylene and propylene). | 03-18-2010 |
20110152580 | PROCESS AND APPARATUS FOR VAPOR PHASE PURIFICATION DURING HYDROCHLORINATION OF MULTI-HYDROXYLATED ALIPHATIC HYDROCARBON COMPOUNDS - A process for converting multihydroxylated-aliphatic hydrocarbon compound(s) and/or ester(s) thereof to chlorohydrins and/or esters thereof is disclosed in which one or more of multihydroxylated-aliphatic hydrocarbon compound(s) and/or ester(s) thereof and/or monochlorohydrin(s) and/or ester(s) thereof with at least one chlorinating feed stream comprising at least one chlorinating agent and at least one impurity having a boiling point below the boiling point of the chlorohydrin product having the lowest boiling under hydrochlorination conditions, optionally in the presence of water, one or more catalyst(s), and/or one or more heavy byproduct(s) in a reaction vessel under hydrochlorination conditions, wherein the liquid-phase reaction mixture is maintained at a temperature below the boiling point of the chlorohydrin product having the lowest boiling point under hydrochlorination conditions and greater than the boiling point(s) of the at least one impurity and a vapor phase vent stream comprising the at least one impurity is removed from the liquid phase reaction mixture. An apparatus suitable for carrying out the disclosed process is illustrated in FIG. | 06-23-2011 |
Patent application number | Description | Published |
20100074949 | Pharmaceutical composition and administration thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 03-25-2010 |
20110256220 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 10-20-2011 |
20120220625 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 08-30-2012 |
20120258983 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-11-2012 |
20130095181 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 04-18-2013 |
20130131107 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 05-23-2013 |
20130158071 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 06-20-2013 |
20140023706 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 01-23-2014 |
20140112988 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 04-24-2014 |
20140163068 | Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases - Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed. | 06-12-2014 |
20140315948 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-23-2014 |